September 26, 2024 01:39 PM EDT

Genentech's Gazyva hits primary endpoint in late-stage kidney disease trial

Katherine Lewin

News Reporter

Genentech plans to expand the label for its CD20-targeting antibody Gazyva following positive late-stage data in an autoimmune disease that impacts the kidneys.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Genentech's Gazyva hits primary endpoint in late-stage kidney disease trial

Katherine Lewin

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for psychiatry

Updated: FDA adcomm votes to limit Opdivo, Keytruda use in stomach, esophageal cancers based on key biomarker

ARCH, biotech's star slugger, snags another $3B for 13th fund

Insilico Medicine, an early force in AI-driven drug R&D, lets IPO plans peter out for second year in a row

Flagship launches startup to design and make lipid nanoparticles for genetic medicines

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

Genen­tech's Gazy­va hits pri­ma­ry end­point in late-stage kid­ney dis­ease tri­al

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Genentech's Gazyva hits primary endpoint in late-stage kidney disease trial